Candesartan Cilexetil
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Candesartan Cilexetil
- Candesartan cilexetil: From Hypertension to Malignant Renovascular Hypertension
Candesartan cilexetil: From Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Candesartan cilexetil is an angiotensin II receptor blocker originally used to treat hypertension. The TxGNN model predicts it may be effective for malignant renovascular hypertension, but there are currently 0 clinical trials and 0 publications directly supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (taken from the drug-disease knowledge base, because the Singapore registration records contain no indication text) |
| Predicted New Indication | Malignant renovascular hypertension |
| TxGNN Prediction Score | 99.68% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 5 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Candesartan is known to be an angiotensin II type 1 (AT1) receptor blocker. Its efficacy in hypertension is established, and mechanistically it may be applicable to renovascular hypertension.
Renovascular hypertension is driven largely by activation of the renin-angiotensin system. Blocking the AT1 receptor is therefore biologically plausible. The new indication is also a severe form of the drug's original indication, hypertension, so it is not a large conceptual leap.
There are two important caveats. First, this is a model prediction only, with no supporting trials or literature. Second, this class of drug carries a known risk in patients with bilateral renal artery stenosis, which is a common cause of renovascular hypertension. A mechanistically sensible link does not guarantee a favourable benefit-risk balance here.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14302P | Candesartan Sandoz Tablet 8mg | Tablet | Not stated in the registration record |
| SIN14301P | Candesartan Sandoz Tablet 16mg | Tablet | Not stated in the registration record |
| SIN10878P | ATACAND Tablet 8 mg | Tablet | Not stated in the registration record |
| SIN10880P | ATACAND Tablet 16 mg | Tablet | Not stated in the registration record |
| SIN11383P | ATACAND PLUS Tablet | Tablet | Not stated in the registration record |
All five registrations are valid and oral. None has been cancelled.
Safety Considerations
- Contraindications (from the drug-disease knowledge graph, not from package insert text): The knowledge graph links candesartan to the following conditions.
- Renal: renal artery obstruction, impaired renal function, anuria.
- Blood pressure and electrolytes: hypotensive disorder, potassium deficiency disease, hypercalcemia, nephrocalcinosis, phosphorus metabolism disease.
- Liver and biliary: liver disease, hepatic coma and encephalopathy, gallbladder disease, neonatal jaundice.
- Metabolic and other: diabetes mellitus, diabetic ketoacidosis, gout, hyperuricemia, hyperparathyroidism, osteitis fibrosa, pancreatitis.
- Autoimmune: systemic lupus erythematosus, including the paediatric form.
Some of these edges probably reflect combination products such as those containing a thiazide diuretic. They should be verified against the actual label. Renal artery obstruction is directly relevant to the predicted indication.
For other safety information, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but there are no trials or publications for malignant renovascular hypertension. The evidence level is L5. The renal artery obstruction link in the safety data adds a specific concern for this indication.
Other predicted indication with more evidence: Among the other predicted indications, cerebrovascular disorder (score 84.9%) has the most supporting evidence, at L1. It is backed by a completed Phase 3 trial of candesartan in acute stroke (SCAST, NCT00120003, 2,500 patients) and several clinical publications, including the ACCESS and CASE-J trials. However, the published SCAST results did not show a benefit of early candesartan in acute stroke and suggested possible harm. The relevance is therefore mainly to long-term secondary prevention. This indication is currently rated "Research Question" and should be reviewed separately.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA)
- Detailed mechanism of action data
- A targeted literature search on ARBs in renovascular hypertension, including the renal artery stenosis risk
- Approved indication text for the Singapore registrations
- A focused review of SCAST outcomes and long-term stroke prevention data if the cerebrovascular direction is pursued
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.